in vitro and in vivo experimental models for drug screening and development for chagas disease
Clicks: 263
ID: 247287
2010
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
263 views
42 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #102 of 450 articles by views in kurdistan journal of applied research
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 450 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Chagas disease, a neglected illness, affects nearly 12-14 million people in endemic areas of Latin America. Although the occurrence of acute cases sharply has declined due to Southern Cone Initiative efforts to control vector transmission, there still remain serious challenges, including the maintenance of sustainable public policies for Chagas disease control and the urgent need for better drugs to treat chagasic patients. Since the introduction of benznidazole and nifurtimox approximately 40 years ago, many natural and synthetic compounds have been assayed against Trypanosoma cruzi, yet only a few compounds have advanced to clinical trials. This reflects, at least in part, the lack of consensus regarding appropriate in vitro and in vivo screening protocols as well as the lack of biomarkers for treating parasitaemia. The development of more effective drugs requires (i) the identification and validation of parasite targets, (ii) compounds to be screened against the targets or the whole parasite and (iii) a panel of minimum standardised procedures to advance leading compounds to clinical trials. This third aim was the topic of the workshop entitled Experimental Models in Drug Screening and Development for Chagas Disease, held in Rio de Janeiro, Brazil, on the 25th and 26th of November 2008 by the Fiocruz Program for Research and Technological Development on Chagas Disease and Drugs for Neglected Diseases Initiative. During the meeting, the minimum steps, requirements and decision gates for the determination of the efficacy of novel drugs for T. cruzi control were evaluated by interdisciplinary experts and an in vitro and in vivo flowchart was designed to serve as a general and standardised protocol for screening potential drugs for the treatment of Chagas disease.
| Reference Key |
romanha2010memriasin
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Alvaro José Romanha;Solange Lisboa de Castro;Maria de Nazaré Correia Soeiro;Joseli Lannes-Vieira;Isabela Ribeiro;André Talvani;Bernadette Bourdin;Bethania Blum;Bianca Olivieri;Carlos Zani;Carmenza Spadafora;Egler Chiari;Eric Chatelain;Gabriela Chaves;José Eduardo Calzada;Juan Manuel Bustamante;Lucio H Freitas-Junior;Luz I Romero;Maria Terezinha Bahia;Michel Lotrowska;Milena Soares;Sonia Gumes Andrade;Tanya Armstrong;Wim Degrave;Zilton de Araújo Andrade |
| Journal | kurdistan journal of applied research |
| Year | 2010 |
| DOI |
10.1590/S0074-02762010000200022
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.